Nā mea maka mitophagy palekana a me nā mea hoʻohui anti-kahiko hou-Urolithin A

ʻO ka mōʻaukala ourolithin A (UA)hiki ke hoʻihoʻi ʻia i ka makahiki 2005. He metabolite ia o nā microorganisms ʻōpū a ʻaʻole hiki ke hoʻopihapiha pololei ʻia ma o nā kahawai meaʻai. Eia nō naʻe, ua waiwai kona mau ellagitannins mua i nā hua like ʻole e like me nā pomegerane a me nā ʻōpena.

Ke kuleana o ka urolithin A

Ma Malaki 25, 2016, ua huki kahi noiʻi nui ma ka makasina "Nature Medicine" i ka manaʻo o ka lehulehu i kona pilina me ka hoʻopaneʻe ʻana i ka ʻelemakule kanaka. Mai ka wā i ʻike ʻia ai i ka makahiki 2016 hiki i ka UA ke hoʻolōʻihi pono i ke ola o C. elegans, ua hoʻohana ʻia ʻo UA ma nā pae āpau (nā cell kumu hematopoietic, nā ʻiʻo ʻili, ka lolo (nā ʻōpū), ka ʻōnaehana pale, ke ola pilikino) a ma nā ʻano like ʻole (C. elegans, melanogaster Ua hōʻike ikaika ʻia nā hopena anti-aging i nā nalo hua, nā ʻiole, a me nā kānaka.

(1) Ke kū'ē i ka ʻelemakule a hoʻoikaika i ka hana ʻiʻo
Ua hōʻike ʻia kahi hoʻokolohua lapaʻau randomized i paʻi ʻia ma JAMA Network Open, he puke pai lālā o ka Journal of the American Medical Association, no ka poʻe ʻelemakule a i ʻole ka poʻe i pilikia i ka neʻe ʻana ma muli o ka maʻi, hiki i nā mea hoʻohui UA ke kōkua i ka hoʻomaikaʻi ʻana i ke olakino ʻiʻo a hana i nā hoʻomaʻamaʻa e pono ai.

(2) Kōkua i ka hoʻoikaika ʻana i ka hiki ke kūʻē i ka puʻupuʻu o ka immunotherapy
I ka makahiki 2022, ua ʻike ka hui noiʻi o Florian R. Greten mai ka Georg-Speyer-Haus Institute of Tumor Biology and Experimental Therapeutics ma Kelemania hiki i ka UA ke hoʻoulu i ka mitophagy i loko o nā pūnaewele T, paipai i ka hoʻokuʻu ʻia ʻana o PGAM5, hoʻāla i ke ala hōʻailona Wnt, a paipai i ka hoʻokumu ʻana o nā pūnaewele kumu hoʻomanaʻo T, no laila e paipai ana i ka pale ʻana i ka maʻi kanesa.

(3) Hoʻohuli i ka ʻelemakule o nā pūnaewele kumu hematopoietic a me ka ʻōnaehana pale
Ma kahi noiʻi i ka makahiki 2023, ua aʻo ke Kulanui o Lausanne ma Switzerland i kona hopena ma ka ʻōnaehana hematopoietic ma ka ʻae ʻana i nā ʻiole 18 mahina e ʻai i ka meaʻai waiwai i ka urolithin A no 4 mau mahina a me ka nānā ʻana i nā loli i loko o kā lākou mau hunaola koko i kēlā me kēia mahina.
Ua hōʻike ʻia nā hopena ua hoʻonui ka ʻai UA i ka helu o nā cell kumu hematopoietic a me nā cell progenitor lymphoid, a ua hoʻemi i ka helu o nā cell progenitor erythroid. Hōʻike kēia ʻike e hiki i kēia ʻai ke hoʻohuli i kekahi o nā loli i ka ʻōnaehana hematopoietic e pili ana me ka ʻelemakule.

(4) Ka hopena anti-inflammatory
ʻOi aku ka ikaika o ka hana anti-inflammatory o UA a hiki ke kāohi nui i nā ʻano kumu mumū like ʻole e like me TNF-α. No kēia kumu, he kuleana ko UA i nā ʻano lapaʻau mumū like ʻole e pili ana i ka lolo, ka momona, ka puʻuwai, ka ʻōpū a me nā ʻiʻo ate. Hiki iā ia ke hōʻoluʻolu i ka mumū ma nā ʻiʻo like ʻole.

(5) Hoʻomalu ʻana i ka lolo
Ua hōʻoia kekahi poʻe akamai e hiki i ka UA ke kāohi i ke ala apoptosis e pili ana i ka mitochondria a hoʻoponopono i ke ala hōʻailona p-38 MAPK, a laila e kāohi ana i ka apoptosis i hoʻokomo ʻia e ka oxidative stress. No ka laʻana, hiki i ka UA ke hoʻomaikaʻi i ka helu ola o nā neurons i hoʻoulu ʻia e ka oxidative stress a he hana neuroprotective maikaʻi.

(6) Ka hopena o ka momona
Hiki i ka UA ke hoʻopilikia i ka metabolism lipid cellular a me ka lipogenesis. Ua hōʻike ʻia nā haʻawina e hiki i ka UA ke hoʻoulu i ka hoʻoulu ʻana o ka momona brown a me ka browning o ka momona keʻokeʻo, me ka pale ʻana i ka hōʻiliʻili ʻana o ka momona i hoʻokumu ʻia e ka ʻai.

(7) Hoʻomaikaʻi i ka momona
Hiki i ka UA ke hōʻemi i ka hōʻiliʻili ʻana o ka momona i loko o nā adipocytes a me nā hunaola akepaʻa i mahi ʻia ma vitro a hoʻonui i ka oxidation momona. Hiki iā ia ke hoʻololi i ka T4 hana ʻole ma ka thyroxine i ka T3 hana nui, e hoʻonui ana i ka wikiwiki metabolic a me ka hana wela ma o ka hōʻailona thyroxine. , no laila e pāʻani ana i kahi kuleana i ka kaohi ʻana i ka momona.

(8) E pale i nā maka
Hiki i ka mitophagy inducer UA ke hōʻemi i ke koʻikoʻi oxidative i ka retina ʻelemakule; hoʻemi ia i ka pae o ka cytosolic cGAS a hōʻemi i ka hoʻāla ʻana o nā cell glial i ka retina ʻelemakule.

(9) Mālama ʻili
Ma waena o nā metabolites ʻōpū mammalian i loaʻa, ʻo UA ka hana antioxidant ikaika loa, ʻo ka lua wale nō i nā proanthocyanidin oligomers, catechins, epicatechin a me 3,4-dihydroxyphenylacetic acid. e kali.

Nā hiʻohiʻona noi ʻo Urolithin A

I ka makahiki 2018, ua koho ʻia ʻo UA e ka US Food and Drug Administration ma ke ʻano he mea ʻai "i ʻike nui ʻia he palekana" a hiki ke hoʻohui ʻia i nā protein shakes, nā mea inu pani meaʻai, ka oatmeal koke, nā protein bars nutritional a me nā mea inu waiū (a hiki i ka 500 mg/lawelawe ʻana)), yogurt Helene, yogurt kiʻekiʻe-protein a me nā protein shakes waiū (a hiki i ka 1000 mg/lawelawe ʻana).

Hiki ke hoʻohui ʻia ka UA i nā huahana mālama ʻili, me nā kirīmi ao, nā kirīmi pō a me nā hui serum, i hoʻolālā ʻia e hoʻonui i ka hydration o ka ʻili a hōʻemi nui i nā wrinkles, hoʻomaikaʻi i ke ʻano o ka ʻili mai loko mai, a hakakā pono i nā hōʻailona ʻike ʻia o ka ʻelemakule. , e kōkua ana i ka ʻili e noho ʻōpiopio.

Ke kaʻina hana ʻana o Urolithin A

(1) Ke kaʻina hana hoʻomoʻa
Hoʻokō mua ʻia ka hana ʻana o UA ma ke kālepa ma o ka ʻenehana fermentation, ka mea i fermented nui ʻia mai nā ʻili pomeraite a he ʻoi aku ka nui o ka urolithin A ma mua o 10%.
(2) Ke kaʻina hana hoʻohuihui kemika
Me ka hana hou a me ka hoʻomohala ʻana o ka noiʻi, ʻo ka synthesis kemika kahi ala nui o ka hana ʻoihana o ka urolithin A. ʻO Suzhou Myland Pharm kahi hui hoʻohui ʻepekema ola hou, synthesis maʻamau a me nā lawelawe hana e hiki ke hāʻawi i nā mea maka pauka urolithin A kiʻekiʻe a nui.